LUPIN LIMITED vs MANKIND PHARMA LIMITED
A side-by-side comparison of LUPIN LIMITED (LUPIN) and MANKIND PHARMA LIMITED (MANKIND) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, LUPIN LIMITED leads LUPIN vs MANKIND on 14 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation40
- Profitability40
- Growth20
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
LUPIN takes 4/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
LUPIN takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
LUPIN takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
LUPIN takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has delivered good profit growth of 37.0% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.1%", "Company's working capital requirements have reduced from 46.4 days to 28.0 days"]
- + ["Company has reduced debt."]
- − ["Promoter holding has decreased over last 3 years: -3.87%"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.